Substances	Interaction	Organism	Category

Substances	Interaction	Organism	Category

Apolipoprotein C1 or apoC1 is a component of chylomicrons and VLDL [R].

APOC1 is primarily produced in the liver and is activated when monocytes change into macrophages. [R]

APOC1 is one the most positively charged proteins in the human body. [R3]

APOC1: Inhibitor of lipoprotein binding to the LDL receptor, LDL receptor-related protein, and very low density lipoprotein (VLDL) receptor. Associates with high density lipoproteins (HDL) and the triacylglycerol-rich lipoproteins in the plasma and makes up about 10% of the protein of the VLDL and 2% of that of HDL. Appears to interfere directly with fatty acid uptake and is also the major plasma inhibitor of cholesteryl ester transfer protein (CETP). Binds free fatty acids and reduces their intracellular esterification. Modulates the interaction of APOE with beta-migrating VLDL and inhibits binding of beta-VLDL to the LDL receptor-related protein.

APOC1 is associated impaired verbal ability (aphasia) and Alzheimers disease. [R, R2, R5]

In a 2013 study, APOC1 was found to be significantly associated with diabetic kidney problems. [R6]

The main function of APOC1 is to inhibit CETP (cholesteryl ester transfer protein), which it does by changing the charge at the proteins surface. [R3, R4]

The ability of APOC1 to inhibit CETP activity is impaired in patients with diabetes. [R4]

Glycation (attachment of sugar) of APOC1 leads to a change in its electric properties, which could account for the loss of CETP inhibition and the increase in CETP activity in people with diabetes. [R4]

In mice, an excess of the APOC1 protein was found to lead to fatty liver and severe insulin resistance in the liver. [R8]

Increases immunitu in response to LPS.  Places an independent role in Alzheimer's risk.  Higher APOC1 lowers fat tissue stores.  Plays a role in memory.

apoC-I and apoC-III inhibit lipolysis by displacing LPL from lipid emulsion particles.

Plasma apolipoprotein CI and CIII levels are associated with increased plasma triglyceride levels and decreased fat mass in men with the metabolic syndrome.

The plasma level of apoC-I was significantly increased in obese individuals compared with healthy individuals.

Data show that apoCI genotype is associated with serum levels of triglycerides and CRP, confirming the role of apoCI in lipid metabolism and suggesting that it also influences inflammation

Condition	Change (log2fold)	Comparison	Species	Experimental variables	Experiment name

Condition	Change (log2fold)	Comparison	Species	Experimental variables	Experiment name

The following transcription factors affect gene expression:

• PPAR-gamma1
• PPAR-gamma2
• Egr-1
• AP-1
• AhR
• c-Jun
• Sp1
• c-Fos
• HNF-3beta

Tissue specificity:

Synthesized mainly in liver and to a minor degree in intestine. Also found in the lung and spleen.

Molecular Function:

• Fatty Acid Binding
• Lipase Inhibitor Activity
• Phosphatidylcholine Binding
• Phosphatidylcholine-Sterol O-Acyltransferase Activator Activity
• Phospholipase Inhibitor Activity

Biological Processes:

• Cholesterol Efflux
• Cholesterol Metabolic Process
• Chylomicron Remnant Clearance
• High-Density Lipoprotein Particle Remodeling
• Lipid Metabolic Process
• Lipoprotein Metabolic Process
• Negative Regulation Of Cholesterol Transport
• Negative Regulation Of Fatty Acid Biosynthetic Process
• Negative Regulation Of Lipid Catabolic Process
• Negative Regulation Of Lipid Metabolic Process
• Negative Regulation Of Lipoprotein Lipase Activity
• Negative Regulation Of Phosphatidylcholine Catabolic Process
• Negative Regulation Of Receptor-Mediated Endocytosis
• Negative Regulation Of Very-Low-Density Lipoprotein Particle Clearance
• Phospholipid Efflux
• Plasma Lipoprotein Particle Remodeling
• Positive Regulation Of Cholesterol Esterification
• Regulation Of Cholesterol Transport
• Triglyceride Metabolic Process
• Very-Low-Density Lipoprotein Particle Assembly
• Very-Low-Density Lipoprotein Particle Clearance

*synonyms